)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
UroGen Pharma
UroGen Pharma (URGN) investor relations material
UroGen Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
ZUSDURI generated $68.0M in Q3 net product revenue, up 35% QoQ, driving total revenue of $89.0M.
Operating income was $8.3M and net loss narrowed to $1.5M; management expects Q4 profitability and positive cash flow.
FDA accepted the UGN-103 NDA with a June 14, 2027 PDUFA date; UGN-501 dosed its first Phase 1 patient.
Financial highlights
Q3 revenue was $89.0M vs. $27.5M a year earlier; gross profit was $81.5M and operating income was $8.3M vs. a $27.4M loss.
Q3 net loss was $1.5M, or $0.03 per share, vs. $33.3M, or $0.69 per share, in Q3 2025.
Q3 R&D expense was $26.0M vs. $14.0M; SG&A was $47.2M vs. $37.6M, reflecting pipeline development and ZUSDURI launch spending.
Nine-month revenue was $212.4M vs. $72.0M; net loss narrowed to $39.4M from $127.1M.
Nine-month operating cash use was $93.5M vs. $124.1M; cash, cash equivalents and marketable securities totaled $90.5M at September 30, 2026.
Outlook and guidance
FY 2026 JELMYTO net product revenue guidance was reduced to ~$90M from $97M-$101M, reflecting a CMS discard-drug provision true-up and trial-related competition affecting starts.
FY 2026 operating expense guidance remains $260M-$270M, expected toward the upper end, including $20M-$24M of non-cash share-based compensation.
Management expects Q4 QoQ ZUSDURI revenue growth despite holiday seasonality; no full-year ZUSDURI guidance was issued.
Profitability and positive cash flow are anticipated in Q4 2026; management expects available capital resources to fund operations through profitability.
UGN-103 NDA review has a June 14, 2027 PDUFA target; LONGVIEW-HR is planned to start in Q4 2026 and UGN-104 Phase 3 enrollment is expected to finish by year-end 2026 or early 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from UroGen Pharma
- Strong demand for Zusduri and advancing pipeline programs signal robust growth prospects.URGN
H.C. Wainwright 28th Annual Global Investment Conference - Zusduri's strong launch and next-gen pipeline position the company for growth and innovation.URGN12th Annual Cantor Fitzgerald Global Healthcare Conference
- ZUSDURI's rapid adoption and robust pipeline position the company for sustained growth.URGNWells Fargo 21st Annual Healthcare Conference
- First-in-class non-surgical therapies and strong pipeline drive innovation in urothelial cancer care.URGNCorporate presentation
- ZUSDURI revenue rose 73% QoQ as Q2 revenue reached $72.5 million and net loss narrowed.URGNQ2 2026
- ZUSDURI's rapid uptake and strong clinical data position it for billion-dollar peak sales.URGNGuggenheim Securities Emerging Outlook: Biotech Summit 2026
- UGN-102 achieved 79.6% CR at 3 months and 82.3% 12-month durability in NMIBC, with low toxicity.URGNStudy Update
- All board proposals passed, with strong product progress and no shareholder questions.URGNAGM 2026
- UGN-102 NDA accepted for June 2025 PDUFA; Jelmyto Q3 sales up, but full-year revenue to miss guidance.URGNQ3 2024
Next UroGen Pharma earnings date
3rd Annual Guggenheim Healthcare Innovation Conference10 Nov, 2026
UroGen Pharma
Next UroGen Pharma earnings date
3rd Annual Guggenheim Healthcare Innovation Conference10 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers. The company utilizes its proprietary RTGel technology, a reverse-thermal hydrogel that enhances the therapeutic profiles of existing drugs by providing longer exposure to the urinary tract tissue, making local therapy more effective. The company is headquartered in Princeton, NJ, with operations in Israel, and its shares are listed on the Nasdaq.